After a big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation in September 2017 when it unveils full details of two key clinical trials tackling the disease in different ways.
The U.S. Centers for Medicare and Medicaid Services said it plans to spend $10 million on advertising for the upcoming Obamacare open enrollment period that starts in November 2017, a sharp cut from the $100 million spent during 2016.
Novartis’s new gene-modifying cancer therapy’s $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even.
Arizona sued Insys Therapeutics Inc., accusing the drugmaker of engaging in a fraudulent marketing scheme aimed at increasing sales of a fentanyl-based cancer pain medicine called Subsys.
After three years Daiichi Sankyo called it quits regarding the company’s partnership with Charleston Laboratories and took a loss of about $250 million.
Incyte Corporation will have an abstract published at the European Society for Medical Oncology (ESMO) meeting in early September with new and updated data from its ongoing Phase I/II trial of epacadostat in combination with Merck & Co.’s Keytruda in advanced melanoma.
Japanese drugmaker Daiichi Sankyo denied that it received a takeover bid during 2016 from Britain’s AstraZeneca.
Amazon.com was hit with a proposed class action lawsuit by a couple who claims defective eclipse glasses purchased through the online retailer damaged their eyes.
Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
People who spend less time in deep, rapid eye movement (REM) sleep may be more likely to develop dementia than individuals who get better quality rest, a recent study suggests.